SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sotera Health Company (SHC) trades at a trailing P/E of 54.9, forward P/E of 16.5. Trailing earnings yield is 1.82%, forward earnings yield 6.05%. PEG 0.80 (Peter Lynch undervalued ≤1.0). Graham Number is $3.63.
Criteria proven by this page:
- VALUE (42/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 16.5 (down from trailing 54.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.80 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.82% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 6.05% as earnings recover.
- Analyst consensus target $22.67 (+42.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 64/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
42/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SHC
Valuation Multiples
P/E (TTM)54.9
Forward P/E16.5
PEG Ratio0.80
Forward PEG0.06
P/B Ratio7.06
P/S Ratio3.68
EV/EBITDA13.9
Per Share Data
EPS (TTM)$0.27
Forward EPS (Est.)$0.96
Book Value / Share$2.13
Revenue / Share$4.10
FCF / Share$0.52
Yields & Fair Value
Earnings Yield1.82%
Forward Earnings Yield6.05%
Dividend Yield0.00%
Graham Number$3.63
SharesGrow IV$22.50 (+41.2%)
Analyst Target$22.67 (+42.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-1,052.5 |
0.00 |
139.28 |
8.28 |
2.85% |
| 2019 |
-342.4 |
-1.70 |
-11.11 |
9.17 |
9.68% |
| 2020 |
-201.3 |
-2.12 |
17.18 |
9.50 |
- |
| 2021 |
56.3 |
-0.14 |
11.22 |
7.06 |
- |
| 2022 |
-10.0 |
0.03 |
6.66 |
2.32 |
- |
| 2023 |
92.2 |
-0.76 |
10.67 |
4.51 |
- |
| 2024 |
87.1 |
-7.84 |
9.55 |
3.52 |
- |
| 2025 |
64.3 |
0.93 |
8.27 |
4.30 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.02 |
$746.15M |
$-5.87M |
-0.8% |
| 2019 |
$-0.07 |
$778.33M |
$-20.85M |
-2.7% |
| 2020 |
$-0.13 |
$818.16M |
$-38.62M |
-4.7% |
| 2021 |
$0.41 |
$931.48M |
$116.88M |
12.5% |
| 2022 |
$-0.83 |
$1B |
$-233.57M |
-23.3% |
| 2023 |
$0.18 |
$1.05B |
$51.38M |
4.9% |
| 2024 |
$0.16 |
$1.1B |
$44.4M |
4% |
| 2025 |
$0.27 |
$1.16B |
$77.95M |
6.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.96 |
$0.92 – $0.98 |
$1.24B |
$1.23B – $1.24B |
5 |
| 2027 |
$1.05 |
$1.01 – $1.07 |
$1.31B |
$1.29B – $1.32B |
5 |
| 2028 |
$1.18 |
$1.09 – $1.26 |
$1.39B |
$1.39B – $1.39B |
2 |
| 2029 |
$1.29 |
$1.28 – $1.30 |
$1.49B |
$1.48B – $1.5B |
1 |
